Please login to the form below

Not currently logged in
Email:
Password:

XLH

This page shows the latest XLH news and features for those working in and with pharma, biotech and healthcare.

SMC enables access to Kyowa Kirin’s Crysvita for rare bone disease

SMC enables access to Kyowa Kirin’s Crysvita for rare bone disease

XLH is usually first observed in infants and is characterised by bowed or bent legs, a short stature, bone pain and delayed walking. ... An application for the extended use of Crysvita in adults with XLH is also currently under review by the EMA.

Latest news

  • NICE U-turn on Crystiva for rare bone disease NICE U-turn on Crystiva for rare bone disease

    This marks a step change in treatment for XLH, emphasised through the emotional testimonies provided by patient groups and clinicians following the first evaluation consultation.”. ... Characterised by bowed or bent legs, a short stature, bone pain and

  • NICE set to reject Kyowa Kirin’s Crysvita for XLH NICE set to reject Kyowa Kirin’s Crysvita for XLH

    The twice-monthly injection was given a conditional approval by the European Medicines Agency (EMA) earlier this year to treat children and young people with X-linked hypophosphataemia (XLH), a genetic ... XLH only affects around 250 children and young

  • Rigel and Ultragenyx claim approvals for rare drugs Rigel and Ultragenyx claim approvals for rare drugs

    Tavalisse and Crysvita are set to treat patients with chronic ITP and XLH, respectively. ... Ultragenyx’s FDA approval was for Crysvita (burosumab), which has become the first approved drug for adults and children ages one year and older with X-linked

More from news
Approximately 3 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Genetic Digital

Genetic Digital specialises in developing digital marketing solutions for the healthcare, medical and pharmaceutical sectors. From developing a digital strategy,...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...